Multimedia Appendix 4

Codebook for all surveys
Includes all branching logic.

<table>
<thead>
<tr>
<th>#</th>
<th>Variable / Field Name</th>
<th>Field Label</th>
<th>Field Attributes (Field Type, Validation, Choices, Calculations, etc.)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>instrument</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Learning Style Survey</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 record_id Record ID text

2 introduction The My Cancer Genome team at Vanderbilt-Ingram Cancer Center (VICC) is conducting a study to improve cancer genetics web pages for oncology physicians and nurses. You are invited to participate in this oncology education program and survey about the concepts of sensitivity and resistance to targeted therapies for ER+ breast cancer.

Here's how it works:
-- Answer a question about your preferred learning format and take a 10-question pre-test.
-- Take a look at the educational materials and answer a few questions.
-- In two weeks, answer a few follow-up questions, and fill out a form to receive your $100 Amazon.com Gift Card.*

Participating will take about 30 minutes. Your participation is totally voluntary and all responses will be confidential. There is very low risk to participating in this survey. You can choose not to answer all of the questions.

Thank you so much for participating. If you have questions or comments contact us via email at mialevy.mycancergenome@vanderbilt.edu or by phone by calling Christine Micheel, Ph.D. (study coordinator and My
Cancer Genome managing editor), at 615-933-9368.

Thank you,

Mia Levy, MD, PhD

Co-Editor in Chief, My Cancer Genome
Assistant Professor of Biomedical Informatics and Medicine
Vanderbilt University Medical Center
2220 Pierce Avenue
691 Preston Research Building
Nashville, TN 37232-6838

<p>| 3 | pin_number | What is the PIN number from your invitation email? This 10-character code can be found in your invitation email. It is case sensitive. Please note that entries associated with incorrect PIN numbers will be ineligible for the $100 Amazon gift card. | text, Required |
| 4 | email | What is your email address? Your email is required to complete the study and for your gift card. Your email will not be used for anything other than the study or after completion of the study. | text (email), Required, Identifier |
| 5 | consent | I agree to participate in this study. | yesno, Required |
| 6 | amazon_disclaimer_1 | *Amazon.com is not a sponsor of this promotion. Except as required by law, Amazon.com Gift Cards (&quot;GCs&quot;) cannot be transferred for value or redeemed for cash. GCs may be used only for purchases of eligible goods at Amazon.com or certain of its affiliated websites. For complete terms and conditions, see <a href="http://www.amazon.com/gc-legal">www.amazon.com/gc-legal</a>. GCs are issued by ACI Gift | descriptive |</p>
<table>
<thead>
<tr>
<th></th>
<th>Column Name</th>
<th>Description</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>active_practice</td>
<td>Are you actively practicing in an oncology setting?</td>
<td>yesno, Required</td>
</tr>
<tr>
<td>8</td>
<td>goodbye</td>
<td>Only individuals actively practicing in an oncology setting are eligible to participate in this study. Thank you for your interest.</td>
<td>descriptive</td>
</tr>
<tr>
<td>9</td>
<td>role_description</td>
<td>Which of the following best describes you?</td>
<td>radio</td>
</tr>
<tr>
<td>10</td>
<td>other_role</td>
<td>Please explain:</td>
<td>text</td>
</tr>
<tr>
<td>11</td>
<td>physician_specialty</td>
<td>Which of the following best describes you?</td>
<td>radio</td>
</tr>
<tr>
<td>12</td>
<td>md_none_of_the_above</td>
<td>If you marked none of the above, please explain.</td>
<td>text</td>
</tr>
<tr>
<td>13</td>
<td>residency_fellowship</td>
<td>How many years has it been since you completed residency/fellowship?</td>
<td>radio</td>
</tr>
</tbody>
</table>

*Cards, Inc., a Washington corporation. All Amazon ®, ™ & © are IP of Amazon.com, Inc. or its affiliates. No expiration date or service fees.*
### Learning Styles

Show the field ONLY if: \[\text{active\_practice} = '1'\]

- I am likely to remember something a year from now if:
  - radio, Required
  - I learn it by reading
  - 100
  - I learn it by listening
  - 010
  - I learn it by watching
  - 001
  - I learn it by reading and listening
  - 110
  - I learn it by reading and watching
  - 101
  - I learn it by listening and watching
  - 011
  - I learn it by reading, listening, and watching
  - 111

### Learning Style Survey Complete

Complete?

- dropdown
  - 0 Incomplete
  - 1 Unverified
  - 2 Complete

**Instrument: Knowledge Pre-Test**

<table>
<thead>
<tr>
<th>Field</th>
<th>Description</th>
<th>Response Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>pretest_rb1</td>
<td>Phosphorylation of RB1 facilitates which of the following:</td>
<td>radio, Required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>20 Tumor suppression</td>
</tr>
<tr>
<td></td>
<td></td>
<td>21 Inhibition of cell cycle progression</td>
</tr>
<tr>
<td></td>
<td></td>
<td>22 Entry into the S phase of the cell cycle</td>
</tr>
<tr>
<td></td>
<td></td>
<td>23 Formation of a Cyclin D1-CDK4/6 complex</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 Don't know</td>
</tr>
<tr>
<td>pretest_acquired_definition</td>
<td>Acquired resistance to endocrine therapy in ER+ breast cancer is defined as recurrence at least 6-12 months after completion of adjuvant therapy or disease progression &gt; 6 months after endocrine therapy initiated in the metastatic setting.</td>
<td>radio, Required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 True</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0 False</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 Don't know</td>
</tr>
<tr>
<td>pretest_primary_definition</td>
<td>Please fill in the blank with the correct answer. Primary resistance to endocrine therapy in ER+ breast cancer has been defined as disease progression less than ____ months after treatment in the metastatic setting.</td>
<td>radio, Required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 6</td>
</tr>
<tr>
<td>Question</td>
<td>Answer Options</td>
<td>Correct Answer</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Estrogen is a steroid hormone that controls cell processes like cell division, growth, differentiation, and proliferation.</td>
<td>radio, Required</td>
<td></td>
</tr>
<tr>
<td>Which of the following is a way primary resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer may occur?</td>
<td>30 Estrogen receptor (ER) amplification, 31 Cyclin D1 amplification, 32 RB1 amplification, 300 None of the above, 100 Don't know</td>
<td></td>
</tr>
<tr>
<td>Which of the following are ways acquired resistance to endocrine therapy in ER+ breast may occur?</td>
<td>40 Activation of growth factor signaling pathways, 41 Changes in the tumor microenvironment, 42 Estrogen receptor mutations, 200 All of the above, 100 Don't know</td>
<td></td>
</tr>
<tr>
<td>Which drug combination is FDA-approved to treat ER+ metastatic breast cancer resistant to letrozole or anastrazole?</td>
<td>50 Everolimus + exemestane, 51 Erlotinib + exemestane, 52 Palbociclib + exemestane, 53 Bevacizumab + exemestane, 100 Don't know</td>
<td></td>
</tr>
<tr>
<td>CDK4/6 inhibitors have only been evaluated in the first line setting in breast cancer.</td>
<td>radio, Required</td>
<td></td>
</tr>
<tr>
<td>The FDA granted accelerated approval of which of the following drug combinations for first line or initial endocrine therapy in postmenopausal women with ER+/HER2-negative advanced breast cancer?</td>
<td>60 Palbociclib + letrozole, 61 Erlotinib + letrozole, 62 Bevacizumab + letrozole, 63 Everolimus + letrozole</td>
<td></td>
</tr>
<tr>
<td></td>
<td>pretest_palbociclib</td>
<td>Palbociclib is in which of the following drug classes?</td>
</tr>
<tr>
<td>---</td>
<td>-------------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>100</td>
<td>Don't know</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>prelearning_material_review_survey_complete</th>
<th>Complete?</th>
<th>dropdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Incomplete</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unverified</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Complete</td>
</tr>
</tbody>
</table>

Instrument: **Link to Learning Materials**

<table>
<thead>
<tr>
<th></th>
<th>learning_materials_link</th>
<th>Please click on the link below to view your learning materials:</th>
<th>descriptive</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td></td>
<td><a href="http://www.mycancergenome.org/learning-material/?record=%5Benrollment_arm_1%5D%5Brecord_id%5D&amp;ls=%5Benrollment_arm_1%5D%5Blearning_styles%5D&amp;pin=%5Benrollment_arm_1%5D%5Bpin_number%5D">Link to Learning Materials</a></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>When you are finished reviewing your learning materials, click the submit button below. You will be taken to a page with a link to the &quot;Post-Learning Material Review Survey.&quot;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>You should also be receiving this link and a link to the next survey by email.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>link_to_learning_materials_complete</th>
<th>Complete?</th>
<th>dropdown</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Incomplete</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unverified</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Complete</td>
</tr>
</tbody>
</table>

Instrument: **Knowledge Post-Test**

<table>
<thead>
<tr>
<th></th>
<th>posttest_palbociclib</th>
<th>Palbociclib is in which of the following drug classes?</th>
<th>radio, Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>29</td>
<td></td>
<td></td>
<td>72 PI3K inhibitors</td>
</tr>
<tr>
<td>Question ID</td>
<td>Question Text</td>
<td>Correct Answer</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td>---------------</td>
<td>----------------</td>
<td></td>
</tr>
<tr>
<td>posttest_cdk46_settings</td>
<td>CDK4/6 inhibitors have only been evaluated in the first line setting in breast cancer.</td>
<td>radio, Required 1 True 0 False 100 Don't know</td>
<td></td>
</tr>
<tr>
<td>posttest_acquired_mechanisms</td>
<td>Which of the following are ways acquired resistance to endocrine therapy in ER+ breast may occur?</td>
<td>radio, Required 42 Estrogen receptor mutations 40 Activation of growth factor signaling pathways 41 Changes in the tumor microenvironment 200 All of the above 100 Don't know</td>
<td></td>
</tr>
<tr>
<td>posttest_acquired_definition</td>
<td>Acquired resistance to endocrine therapy in ER+ breast cancer is defined as recurrence at least 6-12 months after completion of adjuvant therapy or disease progression &gt; 6 months after endocrine therapy initiated in the metastatic setting.</td>
<td>radio, Required 1 True 0 False 100 Don't know</td>
<td></td>
</tr>
<tr>
<td>posttest_fda_approved</td>
<td>Which drug combination is FDA-approved to treat ER+ metastatic breast cancer resistant to letrozole or anastrazole?</td>
<td>radio, Required 53 Bevacizumab + exemestane 50 Everolimus + exemestane 52 Palbociclib + exemestane 51 Erlotinib + exemestane 100 Don't know</td>
<td></td>
</tr>
<tr>
<td>posttest_fda_accelerated</td>
<td>The FDA granted accelerated approval of which of the following drug combinations for first line or initial endocrine therapy in postmenopausal women with ER+/HER2-negative advanced breast cancer?</td>
<td>radio, Required 63 Everolimus + letrozole 60 Palbociclib + letrozole 62 Bevacizumab + letrozole 61 Erlotinib + letrozole 100 Don't know</td>
<td></td>
</tr>
</tbody>
</table>
| posttest_primary_mechanisms | Which of the following is a way primary resistance to endocrine | radio, Required 30 Estrogen receptor (ER)
<table>
<thead>
<tr>
<th>Posttest</th>
<th>Question</th>
<th>Options</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>therapy in estrogen receptor-positive (ER+) breast cancer may occur?</td>
<td>amplification</td>
<td>radio, Required</td>
</tr>
<tr>
<td></td>
<td></td>
<td>32 RB1 amplification</td>
<td>1 True</td>
</tr>
<tr>
<td></td>
<td></td>
<td>31 Cyclin D1 amplification</td>
<td>0 False</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 None of the above</td>
<td>100 Don't know</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 Don't know</td>
<td></td>
</tr>
<tr>
<td>37</td>
<td>Estrogen is a steroid hormone that controls cell processes like cell division, growth, differentiation, and proliferation.</td>
<td>radio, Required</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 True</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0 False</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 Don't know</td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Please fill in the blank with the correct answer. Primary resistance to endocrine therapy in ER+ breast cancer has been defined as disease progression less than ____ months after treatment in the metastatic setting.</td>
<td>radio</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 8</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>6 6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 12</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>10 10</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 Don't know</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Phosphorylation of RB1 facilitates which of the following:</td>
<td>radio</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>20 Tumor suppression</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>22 Entry into the S phase of the cell cycle</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>21 Inhibition of cell cycle progression</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>23 Formation of a cyclin D1-CDK4/6 complex</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>100 Don't know</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Fourteen days after you click the submit survey button below you will receive an email with a link to a 5-minute follow-up survey. Upon completion, you will receive your $100 Amazon.com Gift Card.*</td>
<td>descriptive</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>On the next screen, we will ask you for feedback on the learning materials.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>*Amazon.com is not a sponsor of this promotion. Except as required by law, Amazon.com Gift Cards (&quot;GCs&quot;) cannot be transferred for value or redeemed for cash. GCs may be</td>
<td></td>
</tr>
</tbody>
</table>
used only for purchases of eligible goods at Amazon.com or certain of its affiliated websites. For complete terms and conditions, see www.amazon.com/gc-legal. GCs are issued by ACI Gift Cards, Inc., a Washington corporation. All Amazon ®, ™ & © are IP of Amazon.com, Inc. or its affiliates. No expiration date or service fees.

<table>
<thead>
<tr>
<th>Instrument: Feedback Survey</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
</tr>
<tr>
<td>41</td>
</tr>
<tr>
<td>42</td>
</tr>
<tr>
<td>43</td>
</tr>
<tr>
<td>44</td>
</tr>
</tbody>
</table>
### Instrument: Knowledge Follow-up Test

<table>
<thead>
<tr>
<th>Question</th>
<th>Options</th>
</tr>
</thead>
</table>
| **47 followup_fda_approved** Which drug combination is FDA-approved to treat ER+ metastatic breast cancer resistant to letrozole or anastrazole? | radio, Required  
51 Erlotinib + exemestane  
52 Palbociclib + exemestane  
53 Bevacizumab + exemestane  
50 Everolimus + exemestane  
100 Don't know |
| **48 followup_rb1** Phosphorylation of RB1 facilitates which of the following: | radio, Required  
22 Entry into the S phase of the cell cycle  
21 Inhibition of cell cycle progression  
23 Formation of a Cyclin D1-CDK4/6 complex  
20 Tumor suppression  
100 Don't know |
| **49 followup_palbociclib** Palbociclib is in which of the following drug classes? | radio, Required  
71 CDK4/6 inhibitors  
73 EGFR inhibitors  
70 mTOR inhibitors  
72 PI3K inhibitors  
100 Don't know |
| **50 followup_acquired_mechanisms** Which of the following are ways acquired resistance to endocrine therapy in ER+ breast may occur? | radio, Required  
41 Changes in the tumor microenvironment  
42 Estrogen receptor mutations |
<table>
<thead>
<tr>
<th>Question</th>
<th>Text</th>
<th>Answer</th>
</tr>
</thead>
<tbody>
<tr>
<td>40</td>
<td>Activation of growth factor signaling pathways</td>
<td>40</td>
</tr>
<tr>
<td>200</td>
<td>All of the above</td>
<td>200</td>
</tr>
<tr>
<td>100</td>
<td>Don't know</td>
<td>100</td>
</tr>
<tr>
<td>51</td>
<td><strong>followup_estrogen</strong></td>
<td>Estrogen is a steroid hormone that controls cell processes like cell division, growth, differentiation, and proliferation.</td>
</tr>
<tr>
<td>52</td>
<td><strong>followup_fda_accelerated</strong></td>
<td>The FDA granted accelerated approval of which of the following drug combinations for first line or initial endocrine therapy in postmenopausal women with ER+/HER2-negative advanced breast cancer?</td>
</tr>
<tr>
<td>53</td>
<td><strong>followup_primary_definition</strong></td>
<td>Please fill in the blank with the correct answer. Primary resistance to endocrine therapy in ER+ breast cancer has been defined as disease progression less than ____ months after treatment in the metastatic setting.</td>
</tr>
<tr>
<td>54</td>
<td><strong>followup_primary_mechanisms</strong></td>
<td>Which of the following is a way primary resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer may occur?</td>
</tr>
<tr>
<td>55</td>
<td><strong>followup_cdk46_settings</strong></td>
<td>CDK4/6 inhibitors have only been evaluated in the first line setting in breast cancer.</td>
</tr>
<tr>
<td>56</td>
<td><strong>followup_acquired_definition</strong></td>
<td>Acquired resistance to endocrine therapy in ER+ breast cancer is defined as recurrence at least 6-12 months after completion of adjuvant therapy or disease progression &gt; 6 months after</td>
</tr>
</tbody>
</table>
endocrine therapy initiated in the metastatic setting.

<table>
<thead>
<tr>
<th></th>
<th>followup_survey_complete</th>
<th>Complete?</th>
<th>dropdown</th>
</tr>
</thead>
</table>
| 57 |                          |          | 0 Incomplete  
|    |                          |          | 1 Unverified  
|    |                          |          | 2 Complete   |

**Instrument: Demographics Survey**

<table>
<thead>
<tr>
<th></th>
<th>practice_type</th>
<th>What is your practice type?</th>
<th>radio</th>
</tr>
</thead>
</table>
| 58 |              |                             | 1 Academic  
|    |              |                             | 3 Community  
|    |              |                             | 4 Both  
|    |              |                             | 5 Other  |

*Show the field ONLY if: [practice_type] = '5'*

<table>
<thead>
<tr>
<th></th>
<th>other_practicetype</th>
<th>Other</th>
<th>text</th>
</tr>
</thead>
<tbody>
<tr>
<td>59</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>percentage_breastpatients</th>
<th>What is the percentage of patients seen with breast cancer in your practice?</th>
<th>radio</th>
</tr>
</thead>
</table>
| 60 |                           |                                                                                                 | 1 Less than 25%  
|    |                           |                                                                                                 | 2 25%-50%  
|    |                           |                                                                                                 | 3 Greater than 50%  
|    |                           |                                                                                                 | 4 Unknown  |

<table>
<thead>
<tr>
<th></th>
<th>age_years</th>
<th>What is your age (years)?</th>
<th>text (integer, Min: 18, Max: 120)</th>
</tr>
</thead>
<tbody>
<tr>
<td>61</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>gender</th>
<th>What is your gender?</th>
<th>radio</th>
</tr>
</thead>
</table>
| 62 |        |                     | 1 Male  
|    |        |                     | 2 Female  
|    |        |                     | 3 Prefer not to say  |

<table>
<thead>
<tr>
<th></th>
<th>ethnicity</th>
<th>Ethnicity:</th>
<th>radio</th>
</tr>
</thead>
</table>
| 63 |           |            | 1 Hispanic or Latino  
|    |           |            | 2 Non-Hispanic  
|    |           |            | 3 Prefer not to say  |

<table>
<thead>
<tr>
<th></th>
<th>race</th>
<th>Race: <em>Check all that apply.</em></th>
<th>checkbox</th>
</tr>
</thead>
</table>
| 64 |      |                                | 1 ethnicity__1 White  
|    |      |                                | 3 ethnicity__3 Black or African American  
<p>|    |      |                                | 4 ethnicity__4 Native Hawaiian or Other Pacific  |</p>
<table>
<thead>
<tr>
<th>Field</th>
<th>Description</th>
<th>Type</th>
<th>Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>ethnicity__5</td>
<td></td>
<td>Islander</td>
</tr>
<tr>
<td>6</td>
<td>ethnicity__6</td>
<td></td>
<td>Asian</td>
</tr>
<tr>
<td>6</td>
<td>ethnicity__6</td>
<td></td>
<td>American Indian or Alaska Native</td>
</tr>
<tr>
<td>97</td>
<td>ethnicity__97</td>
<td></td>
<td>Other</td>
</tr>
<tr>
<td>99</td>
<td>ethnicity__99</td>
<td></td>
<td>Unknown</td>
</tr>
<tr>
<td>98</td>
<td>ethnicity__98</td>
<td></td>
<td>Prefer not to say</td>
</tr>
<tr>
<td>65</td>
<td>demographics_survey_complete</td>
<td>Complete?</td>
<td>dropdown</td>
</tr>
<tr>
<td>66</td>
<td>send_my_gift_card</td>
<td>I want to receive the $100 Amazon Gift Card.</td>
<td>yesno, Required</td>
</tr>
<tr>
<td>67</td>
<td>vanderbilt_employee</td>
<td>Are you a Vanderbilt University or Vanderbilt University Medical Center employee (faculty, staff, or other)?</td>
<td>yesno, Required</td>
</tr>
<tr>
<td>68</td>
<td>ssn</td>
<td>Please provide your social security number.</td>
<td>text, Required, Identifier</td>
</tr>
<tr>
<td>69</td>
<td>vu_finance</td>
<td>The Vanderbilt University Finance Department requires us to collect your name and address to issue your gift card. Your information will not be used for anything other than to send the gift card, and it will not be used after completion of the study.</td>
<td>descriptive</td>
</tr>
<tr>
<td>70</td>
<td>first_name</td>
<td>First Name</td>
<td>text, Required, Identifier</td>
</tr>
<tr>
<td>71</td>
<td>middle_initial</td>
<td>Middle Initial</td>
<td>text, Identifier</td>
</tr>
<tr>
<td>72</td>
<td>last_name</td>
<td>Last Name</td>
<td>text, Required, Identifier</td>
</tr>
<tr>
<td>73</td>
<td>address_1</td>
<td>Address Line 1</td>
<td>text, Required, Identifier</td>
</tr>
<tr>
<td></td>
<td>Field</td>
<td>Description</td>
<td>Values</td>
</tr>
<tr>
<td>----</td>
<td>------------------------------------------</td>
<td>------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>74</td>
<td>address_2</td>
<td>Address Line 2</td>
<td>text, Identifier</td>
</tr>
<tr>
<td>75</td>
<td>city</td>
<td>City</td>
<td>text, Required, Identifier</td>
</tr>
<tr>
<td>76</td>
<td>state</td>
<td>State</td>
<td>dropdown, Required</td>
</tr>
<tr>
<td></td>
<td>Show the field ONLY if:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[send_my_gift_card] = '1'</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>1 Alabama</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2 Alaska</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>3 American Samoa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>4 Arizona</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>5 Arkansas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>6 California</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>7 Colorado</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>8 Connecticut</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>9 Delaware</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>10 District of Columbia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>11 Florida</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>12 Georgia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>13 Guam</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>14 Hawaii</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>15 Idaho</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>16 Illinois</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>17 Indiana</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>18 Iowa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>19 Kansas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>20 Kentucky</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>21 Louisiana</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>22 Maine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>23 Maryland</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>24 Massachusetts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>25 Michigan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>26 Minnesota</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>27 Mississippi</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>28 Missouri</td>
<td></td>
<td></td>
</tr>
<tr>
<td>zip</td>
<td>Text</td>
<td>Identifier</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>77</td>
<td>Zip Code</td>
<td>text, Identifier</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>md_nonphysician</th>
<th>Text</th>
<th>Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>78</td>
<td>I have an M.D. or equivalent degree (e.g., D.O., M.B.B.S)</td>
<td>yesno, Required</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>1</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No</td>
</tr>
<tr>
<td>Field</td>
<td>Validation</td>
</tr>
<tr>
<td>----------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>[role_description] = '3' or [enrollment_arm_1] [role_description] = '4' or [enrollment_arm_1] [role_description] = '5' or [enrollment_arm_1] [role_description] = '6')</td>
<td>Are you legally authorized to practice medicine in the United States?</td>
</tr>
<tr>
<td>country</td>
<td>Show the field ONLY if: [send_my_gift_card] = '1' and ( [enrollment_arm_1] [role_description] = '1' or [md_nonphysician] = '1')</td>
</tr>
<tr>
<td>sunshine_act</td>
<td>Show the field ONLY if: [country] = '1' AND [send_my_gift_card] = '1' AND ( [enrollment_arm_1] [role_description] = '1' or [md_nonphysician] = '1')</td>
</tr>
<tr>
<td>credential</td>
<td>Show the field ONLY if: [country] = '1' and ( [enrollment_arm_1] [role_description] = '1' or [md_nonphysician] = '1')</td>
</tr>
<tr>
<td>other_credential</td>
<td>Show the field ONLY if: [credential] = '4'</td>
</tr>
<tr>
<td>npi_id</td>
<td>Show the field ONLY if: [country] = '1' and ( [enrollment_arm_1] [role_description] = '1' or [md_nonphysician] = '1')</td>
</tr>
<tr>
<td>amazon_disclaimer_2</td>
<td>*Amazon.com is not a sponsor of this promotion. Except as required by law, Amazon.com Gift Cards (&quot;GCs&quot;) cannot be transferred for value or redeemed for cash. GCs may be used only for purchases of eligible goods at Amazon.com</td>
</tr>
</tbody>
</table>
or certain of its affiliated websites. For complete terms and conditions, see www.amazon.com/gc-legal. GCs are issued by ACI Gift Cards, Inc., a Washington corporation. All Amazon ®, ™ & © are IP of Amazon.com, Inc. or its affiliates. No expiration date or service fees.

<table>
<thead>
<tr>
<th>85</th>
<th>amazon_gift_card_complete</th>
<th>Complete?</th>
<th>dropdown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Incomplete</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Unverified</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Complete</td>
</tr>
</tbody>
</table>